Moderna, Inc. Stock-Based Compensation
Moderna, Inc. (MRNA) reported Stock-Based Compensation of $224.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-31
- Moderna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $120.00M, a 7.69% decline year-over-year.
- Moderna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $104.00M, a 9.57% decline year-over-year.
- Moderna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $113.00M, a 8.65% increase year-over-year.
- Moderna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $125.00M, a 11.61% increase year-over-year.
- Moderna, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $483.00M, a 12.59% increase from fiscal 2024.
- Moderna, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $429.00M, a 40.66% increase from fiscal 2023.
- Moderna, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $305.00M, a 34.96% increase from fiscal 2022.
- Moderna, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $226.00M, a 59.15% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $224.00M 10-Q · filed 2026-07-31 | $337.00M derived: sum of 3 quarters · filed 2026-07-31 | $462.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $104.00M 10-Q · filed 2026-05-01 | $217.00M derived: sum of 2 quarters · filed 2026-05-01 | $342.00M derived: sum of 3 quarters · filed 2026-05-01 | $472.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $113.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $238.00M derived: sum of 2 quarters · filed 2026-02-20 | $368.00M derived: sum of 3 quarters · filed 2026-07-31 | $483.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $125.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $255.00M derived: sum of 2 quarters · filed 2026-07-31 | $370.00M 10-Q · filed 2025-11-06 | $474.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $130.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $245.00M 10-Q · filed 2026-07-31 | $349.00M derived: sum of 3 quarters · filed 2026-07-31 | $461.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $115.00M 10-Q · filed 2026-05-01 | $219.00M derived: sum of 2 quarters · filed 2026-05-01 | $331.00M derived: sum of 3 quarters · filed 2026-05-01 | $443.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $104.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $216.00M derived: sum of 2 quarters · filed 2026-02-20 | $328.00M derived: sum of 3 quarters · filed 2026-02-20 | $429.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $112.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $224.00M derived: sum of 2 quarters · filed 2025-11-06 | $325.00M 10-Q · filed 2025-11-06 | $404.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $112.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $213.00M 10-Q · filed 2025-08-01 | $292.00M derived: sum of 3 quarters · filed 2026-02-20 | $369.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $101.00M 10-Q · filed 2025-05-01 | $180.00M derived: sum of 2 quarters · filed 2026-02-20 | $257.00M derived: sum of 3 quarters · filed 2026-02-20 | $331.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $156.00M derived: sum of 2 quarters · filed 2026-02-20 | $230.00M derived: sum of 3 quarters · filed 2026-02-20 | $305.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $77.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $151.00M derived: sum of 2 quarters · filed 2024-11-07 | $226.00M 10-Q · filed 2024-11-07 | $288.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $74.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $149.00M 10-Q · filed 2024-08-01 | $211.00M derived: sum of 3 quarters · filed 2025-02-21 | $281.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $75.00M 10-Q · filed 2024-05-02 | $137.00M derived: sum of 2 quarters · filed 2025-02-21 | $207.00M derived: sum of 3 quarters · filed 2025-02-21 | $257.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $132.00M derived: sum of 2 quarters · filed 2025-02-21 | $182.00M derived: sum of 3 quarters · filed 2025-02-21 | $226.00M 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $120.00M derived: sum of 2 quarters · filed 2023-11-03 | $164.00M 10-Q · filed 2023-11-03 | $201.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $94.00M 10-Q · filed 2023-08-03 | $131.00M derived: sum of 3 quarters · filed 2024-02-23 | $171.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $44.00M 10-Q · filed 2023-05-04 | $81.00M derived: sum of 2 quarters · filed 2024-02-23 | $121.00M derived: sum of 3 quarters · filed 2024-02-23 | $156.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $77.00M derived: sum of 2 quarters · filed 2024-02-23 | $112.00M derived: sum of 3 quarters · filed 2024-02-23 | $142.00M 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $40.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $75.00M derived: sum of 2 quarters · filed 2022-11-03 | $105.00M 10-Q · filed 2022-11-03 | $131.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $65.00M 10-Q · filed 2022-08-03 | $91.00M derived: sum of 3 quarters · filed 2023-02-24 | $113.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $30.00M 10-Q · filed 2022-05-04 | $56.00M derived: sum of 2 quarters · filed 2023-02-24 | $78.00M derived: sum of 3 quarters · filed 2023-02-24 | $103.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $48.00M derived: sum of 2 quarters · filed 2023-02-24 | $73.00M derived: sum of 3 quarters · filed 2023-02-24 | $93.00M 10-K · filed 2023-02-24 | $93.02M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $47.00M derived: sum of 2 quarters · filed 2021-11-04 | $67.00M 10-Q · filed 2021-11-04 | $67.54M 10-Q · filed 2020-10-30 | $87.20M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $45.00M 10-Q · filed 2021-08-05 | $44.34M 10-Q · filed 2020-08-06 | $65.20M derived: sum of 3 quarters · filed 2022-02-25 | $86.01M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $20.00M 10-Q · filed 2021-05-06 | $20.41M 10-Q · filed 2020-05-07 | $40.20M derived: sum of 2 quarters · filed 2022-02-25 | $61.01M derived: sum of 3 quarters · filed 2022-02-25 | $82.50M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $20.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $41.01M derived: sum of 2 quarters · filed 2022-02-25 | $62.50M derived: sum of 3 quarters · filed 2022-02-25 | $81.00M 10-K · filed 2022-02-25 | $81.12M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $20.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $42.30M derived: sum of 2 quarters · filed 2020-10-30 | $60.80M 10-Q · filed 2020-10-30 | $92.44M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $39.99M 10-Q · filed 2020-08-06 | $71.63M derived: sum of 3 quarters · filed 2021-02-26 | $86.35M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $18.50M 10-Q · filed 2020-05-07 | $50.14M derived: sum of 2 quarters · filed 2021-02-26 | $64.86M derived: sum of 3 quarters · filed 2021-02-26 | $79.21M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $31.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $46.36M derived: sum of 2 quarters · filed 2021-02-26 | $60.71M derived: sum of 3 quarters · filed 2021-02-26 | $72.56M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $14.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $29.07M derived: sum of 2 quarters · filed 2019-11-06 | $40.92M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $14.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $26.20M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $11.85M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $40.05M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $39.36M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |